期刊文献+

蛋白酶抑制剂类抗癌药物的研究进展 被引量:2

Research Progress of Anticancer Drugs of Protease Inhibitor
下载PDF
导出
摘要 肿瘤细胞对蛋白质水平的要求异于正常细胞,蛋白酶抑制剂类药物对肿瘤细胞生长有明显抑制作用,并且对免疫类与炎症类疾病颇具疗效。对各种蛋白酶抑制剂类新药进行了评述,重点介绍了硼替佐米的结构、性质和合成。 The requirements of proteins between normal and tumor cells are different.Researches suggest that protease inhibitor drugs can inhibit the growth of tumor cells significantly,and have good effect on the immune and inflammatory diseases as well.This article gives an introduction about the protease inhibitor drugs,with special attention to one new kind of medicine——bortezomib.
出处 《化学与生物工程》 CAS 2011年第6期7-11,共5页 Chemistry & Bioengineering
基金 山东省自然科学基金资助项目(2009ZRB01220)
关键词 蛋白酶体 蛋白质 抑制剂 肿瘤 抗癌 硼替佐米 proteasome protein inhibitor tumor anticancer bortezomib
  • 相关文献

参考文献1

二级参考文献12

  • 1李江,陈又南,段嘉川,曾理,李尤,王莉.ErbB信号与蛋白激酶B在快速起搏所致猴心衰心肌细胞损伤中的作用[J].药学学报,2007,42(5):470-474. 被引量:5
  • 2Ip SW, Weng YS, Lin SY, et al. The role of Ca^2+ on rhein-induced apoptosis in human cervical cancer Ca Ski cells [ J ]. Anticancer Res, 2007,27:379 - 389.
  • 3Lin ML, Chen SS, Lu YC, et al. Rhein induces apoptosis through induction of endoplasmic reticulum stress and Ca^2+ -dependent mitochondrial death pathway in human nasopharyngeal carcinoma cells [ J ]. Anticancer Res, 2007,27:3313 - 3322.
  • 4Whenham N, D'Hondt V, Piccart MJ. HER-2-positive breast cancer: from trastuzumab to innovatory anti-HER2 strategies [J]. Clin Breast Cancer, 2008,8:38-49.
  • 5Nishimura R, Okumura Y, Arima N. Trastuzumab monotherapy versus combination therapy for treating recurrent breast cancer: time to progression and survival [ J]. Breast Cancer, 2008,15:57 - 64.
  • 6Doyle DM, Miller KD. Development of new targeted therapies for breast cancer [ J]. Breast Cancer, 2008, 15:49 - 56.
  • 7Bender LM, Nahta R. HER-2 cross talk and therapeutic resistance in breast cancer [J]. Front Biosci, 2008,13: 3906 - 3912.
  • 8Xu H, Yu Y, Marciniak D, et al. Epidermal growth factor receptor (EGFR)-related protein inhibits multiple members of the EGFR family in colon and breast cancer cells [J]. Mol Cancer Ther, 2005,4:435-442.
  • 9Kong A, Calleja V, Leboucher P, et al. HER2 oncogenic function escapes EGFR tyrosine kinase inhibitors via activation of alternative HER receptors in breast cancer cells [J]. PLoS ONE, 2008,3:e2881.
  • 10Dieras V, Vincent-Salomon A, Degeorges A, et al. Trastuzumab (Herceptin) and breast cancer: mechanisms of resistance [ J]. Bull Cancer, 2007,94:259 - 266.

共引文献14

同被引文献26

  • 1郭振兴,金洁,吴灵娇.AS_2O_3对多发性骨髓瘤细胞凋亡及其对自分泌VEGF的影响[J].实用肿瘤杂志,2005,20(3):231-233. 被引量:7
  • 2孙启鑫,孟凡义,扶云碧,李利.硼替佐米单用或联合三尖杉酯碱体外诱导HL-60细胞凋亡实验研究[J].中国实验血液学杂志,2007,15(2):233-236. 被引量:15
  • 3李利,孟凡义,扶云碧,蔡艳霞,孙启鑫.硼替佐米或联合三氧化二砷治疗HL-60白血病细胞移植瘤裸鼠的实验研究[J].南方医科大学学报,2007,27(10):1504-1506. 被引量:2
  • 4Adams J. The proteasome : a suitable antineoplastic target [ J ]. Nat Rev Cancer, 2004,4(5) :349-360.
  • 5Boccadoro M, Morgan G, Cavenagh J. Preclinical evaluation of the proteasome inhibitor bortezomib in cancer therapy[J]. Cancer Cell Int, 2005,5(1) :18.
  • 6Paramore A, Frantz S. Bortezomib [ J ]. Nat Rev Drug Discov, 2003,2(8) :611-612.
  • 7Papandreou CN, Daliani DD, Nix D, et al. Phase I trial of the protea- some inhibitor bortezomib in patients with advanced solid tumors with observations in androgen-independent prostate cancer [ J 1. J Clin On- col, 2004,22(11) :2108-2121.
  • 8Goy A, Younes A, McLaughlin P, et al. Phase Ⅱ study of protea- some inhibitor bortezomib in relapsed or refractory B-cell non- Hodgkin's lymphoma[ J]. J Clin Oncol, 2005,23 (4):667-675.
  • 9Fisher RI, Bernstein SH, Kahl BS, et al. Muhicenter phase Ⅱstudy of bortezomib in patients with relapsed or refractory mantle cell lymphoma [ J ]. J Clin Oncol, 2006,24 (30) :4867 4874.
  • 10Goy A, Bernstein SH, Kahl BS, et al. Bortezomib in patients with relapsed or refractory mantle cell lymphoma : updated time-to-event analyses of the muhicenter phase 2 PINNACLE study [ J]. Ann Oncol, 2009,20(3) :520-525.

引证文献2

二级引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部